Get the Stockscreener App
13.90
5.39%
0.72
Capricor Therapeutics Inc stock is traded at $13.90, with a volume of 702.94K.
It is up +5.39% in the last 24 hours and up +90.27% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$13.18
Open:
$13.255
24h Volume:
702.94K
Relative Volume:
0.35
Market Cap:
$635.37M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-16.75
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
+40.44%
1M Performance:
+90.27%
6M Performance:
-6.53%
1Y Performance:
+153.47%
1-Day Range:
$12.80
$13.99
1-Week Range:
$9.53
$13.99
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
13.90 | 461.19M | 27.10M | -24.31M | -33.33M | -0.83 |
|
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.57 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.10 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
498.00 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Announces Equity Incentive Plan By Investing.com - Investing.com South Africa
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock Ne - GuruFocus
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Equity Incentive Plan - Investing.com
Capricor Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect - ACCESS Newswire
D. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Janus Henderson Group PLC Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Cut to “Sell” at Wall Street Zen - Defense World
Capricor Therapeutics’ Buy Thesis Ahead Of Deramiocel PDUFA Date (NASDAQ:CAPR) - Seeking Alpha
What is Roth Capital’s Estimate for CAPR Q2 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Roth Capital Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Analysts Set Expectations for CAPR FY2026 Earnings - Defense World
Uncertainties Regarding Capricor's CAP-1002 Approval (NASDAQ:CAPR) - Seeking Alpha
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision - Seeking Alpha
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Northern Trust Corp Boosts Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy - Value The Markets
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript - MSN
Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating - marketscreener.com
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Capricor Therapeutics (CAPR): Roth Capital Sees Strong Growth Po - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Research Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
How to Take Advantage of moves in (CAPR) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Invests $197,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparations - MSN
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair - simplywall.st
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results - Yahoo Finance
Capricor Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
1.30%
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):